The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

T Cell Activation Is Associated with Lower CD4⁺T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

Peter W. Hunt, Jeffrey N. Martin, Elizabeth Sinclair et al. · The Journal of Infectious Diseases · 2003 · 845 citations · Full text

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Roy T. Steigbigel, David A. Cooper, Princy Kumar et al. · New England Journal of Medicine · 2008 · 683 citations · Full text

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

Sarah Palmer, Frank Maldarelli, Ann Wiegand et al. · Proceedings of the National Academy of Sciences · 2008 · 641 citations · Full text

Low-level Viremia Persists, Immunology, Antiviral Drug +16

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin et al. · The Lancet · 2009 · 619 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +8

New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma

Sarah Palmer, Ann Wiegand, Frank Maldarelli et al. · Journal of Clinical Microbiology · 2003 · 608 citations · Full text